12 September 2024
12 September 2024
Children aged 6-12 years achieved a 5.8% reduction in BMI with Saxenda at 52 weeks in a Phase IIIa trial.
Tebapivat is intended for the treatment of myelodysplastic syndromes.
According to GlobalData, combination therapy is the future of metabolic disease treatment, thus Pep2Tango’s candidate will find its space.
NTX-001 is intended for the treatment of peripheral nerve injury that requires repair.
In trials, plozasiran has shown promising results by reducing triglycerides and other atherogenic lipoproteins.
The IBA-SCK CEN joint venture secured funds to increase production of the radioisotope used in cancer therapies.
The suspension is on the grounds of unauthorised claims that the product reduces the need for reading glasses.
The FDA's decision was informed by the results of the Phase II/III QUASAR study of the asset.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
